Cargando…
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
INTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased towa...
Ejemplares similares
-
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
por: Stamate, Daniel, et al.
Publicado: (2019) -
Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019) -
Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
por: Xu, Jin, et al.
Publicado: (2021) -
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020) -
Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
por: Homann, Jan, et al.
Publicado: (2022)